Treating Alopecia Areata: Current Practices Versus New Directions

American Journal of Clinical Dermatology

Volumn 18, Issue 1, 2017, Pages 67-75

  Gupta, Aditya K ^a,b   Carviel, Jessie ^b   Abramovits, William ^c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Dermatology Treatment and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; APREMILAST; AZATHIOPRINE; BIMATOPROST; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; DIPHENCYPRONE; EZETIMIBE PLUS SIMVASTATIN; INTERLEUKIN 2; JANUS KINASE INHIBITOR; METHOTREXATE; MINOXIDIL; SALAZOSULFAPYRIDINE; SQUARIC ACID DIBUTYL ESTER; TUMOR NECROSIS FACTOR INHIBITOR; DERMATOLOGICAL AGENT; GLUCOCORTICOID;

ACNE; ALOPECIA AREATA; APPLICATION SITE BURNING; ARTHRALGIA; ASTHENIA; BLISTER; CATARACT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONJUNCTIVITIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DERMATITIS; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; ECZEMA; EDEMA; ERYTHEMA MULTIFORME; EXCIMER LASER; EXPERIMENTAL THERAPY; EYE IRRITATION; FEVER; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPEREMIA; HYPERPIGMENTATION; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; KIDNEY DYSFUNCTION; LENTIGO; LEUKODERMA; LOW LEVEL LASER THERAPY; LYMPHADENOPATHY; LYMPHOCYTOPENIA; NAUSEA; NONHUMAN; OLIGOMENORRHEA; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN ATROPHY; STAPHYLOCOCCUS INFECTION; SWELLING; SYSTEMIC THERAPY; THROMBOCYTE RICH PLASMA; TOPICAL TREATMENT; URTICARIA; VIRUS MENINGITIS; WEAKNESS; XEROSIS; ANIMAL; PATHOLOGY; PROCEDURES; RECURRENT DISEASE;

ALOPECIA AREATA; ANIMALS; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; LASER THERAPY; PLATELET-RICH PLASMA; RECURRENCE;

EID: 85011883693     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-016-0230-4     Document Type: Review

References (117)

1. Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64–9.
2. McElwee K, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R. Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol. 2001;11(1):11–6.
3. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–26.
4. Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107–15.
5. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008;2:CD004413.
6. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG, British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149(4):692–9.
7. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol JDD. 2009;8(10):909–12.
8. Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol. 1973;88(1):55–9.
9. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11(6):478–83.
10. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05 % under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49(1):96–8.
11. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica. 1970;141(3):193–202.
12. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2 % topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128(11):1467–73.
13. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol. 2005;52(2):287–90.
14. Seiter S, Ugurel S, Tilgen W, Reinhold U. High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatol Basel Switz. 2001;202(3):230–4.
15. Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol. 1998;39(4 Pt 1):597–602.
16. Sladden MJ, Hutchinson PE. Is oral pulsed prednisolone useful in alopecia areata? Critical appraisal of a randomized trial. J Am Acad Dermatol. 2005;53(6):1100–1 (author reply 1101).
17. Iorizzo M, Tosti A. Treatments options for alopecia. Expert Opin Pharmacother. 2015;16(15):2343–54.
18. Senila SC, Danescu SA, Ungureanu L, Candrea E, Cosgarea RM. Intravenous methylprednisolone pulse therapy in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2015;81(1):95.
19. Im M, Lee SS, Lee Y, Kim CD, Seo YJ, Lee JH, et al. Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J Dermatol. 2011;38(8):767–72.
20. Nakajima T, Inui S, Itami S. Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatol Basel Switz. 2007;215(4):320–4.
21. Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol. 1975;55(6):493–6.
22. Açıkgöz G, Ozmen I, Cayırlı M, Yeniay Y, Köse O. Pulse methylprednisolone therapy for the treatment of extensive alopecia areata. J Dermatol Treat. 2014;25(2):164–6.
23. Staumont-Sallé D, Vonarx M, Lengrand F, Segard M, Delaporte E. Pulse corticosteroid therapy for alopecia areata: long-term outcome after 10 years. Dermatol Basel Switz. 2012;225(1):81–7.
24. Ait Ourhroui M, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a once-monthly oral pulse. Ann Dermatol Vénéréol. 2010;137(8–9):514–8.
25. Bin Saif GA, Al- Khawajah MM, Al- Otaibi HM, Al- Roujayee AS, Alzolibani AA, Kalantan HA, et al. Efficacy and safety of oral mega pulse methylprednisolone for severe therapy resistant alopecia areata. Saudi Med J. 2012;33(3):284–91.
26. Lalosevic J, Gajic-Veljic M, Bonaci-Nikolic B, Nikolic M. Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study. Dermatol Ther. 2015;28(5):309–17.
27. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137(8):1063–8.
28. van der Steen PH, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin. 1993;11(3):619–22.
29. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res. 1980;267(1):109–14.
30. Orecchia G, Perfetti L. Alopecia areata and topical sensitizers: allergic response is necessary but irritation is not. Br J Dermatol. 1991;124(5):509.
31. Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichology. 2010;2(1):36.
32. Tosti A, De Padova MP, Minghetti G, Veronesi S. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol. 1986;15(2 Pt 1):209–10.
33. Ro BI. Alopecia areata in Korea (1982–1994). J Dermatol. 1995;22(11):858–64.
34. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5 Pt 1):751–61.
35. Pan R, Liu J, Xuan X, Li B. Chinese experience in the treatment of alopecia areata with diphenylcyclopropenone. J Dermatol. 2015;42(2):220–1.
36. Chiang K, Atanaskova Mesinkovska N, Amoretti A, Piliang MP, Kyei A, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Am Acad Dermatol. 2014;71(3):595–7.
37. Wilkerson MG, Connor TH, Henkin J, Wilkin JK, Matney TS. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol. 1987;17(4):606–11.
38. Tosti A, Piraccini BM, Misciali C, Vincenzi C. Lentiginous eruption due to topical immunotherapy. Arch Dermatol. 2003;139(4):544–5.
39. Micali G, Cicero RL, Nasca MR, Sapuppo A. Treatment of alopecia areata with squaric acid dibutylester. Int J Dermatol. 1996;35(1):52–6.
40. Case PC, Mitchell AJ, Swanson NA, Vanderveen EE, Ellis CN, Headington JT. Topical therapy of alopecia areata with squaric acid dibutylester. J Am Acad Dermatol. 1984;10(3):447–50.
41. Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol. 2004;13(1):5–10.
42. Tang L, Cao L, Pelech S, Lui H, Shapiro J. Cytokines and signal transduction pathways mediated by anthralin in alopecia areata-affected Dundee experimental balding rats. J Investig Dermatol Symp Proc Soc Investig Dermatol Inc Eur Soc Dermatol Res. 2003;8(1):87–90.
43. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1491–3.
44. Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol. 1979;115(10):1254–5.
45. Bornhövd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol. 2001;45(5):736–43.
46. Hunter N, Shaker O, Marei N. Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J Dermatol Treat. 2011;22(1):2–10.
47. Feldmann KA, Kunte C, Wollenberg A, Wolfe H. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol. 2002;147(5):1031–2.
48. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52(1):138–9.
49. Ucak H, Kandi B, Cicek D, Halisdemir N, Dertlıoğlu SB. The comparison of treatment with clobetasol propionate 0.05 % and topical pimecrolimus 1 % treatment in the treatment of alopecia areata. J Dermatol Treat. 2012;23(6):410–20.
50. Rigopoulos D, Gregoriou S, Korfitis C, Gintzou C, Vergou T, Katrinaki A, et al. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol. 2007;32(4):456–7.
51. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):730–6.
52. Fiedler-Weiss VC. Topical minoxidil solution (1 % and 5 %) in the treatment of alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):745–8.
53. Zaheri S, Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 2010;35(4):e161–2.
54. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009;60(4):705–6.
55. Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61(3):530–2.
56. Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol. 2010;2(2):86–8.
57. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: a pilot study. Dermatol Basel Switz. 2015;230(4):308–13.
58. Li AW, Antaya RJ. Successful treatment of pediatric alopecia areata of the scalp using topical bimatoprost. Pediatr Dermatol. 2016;33(5):e282–3.
59. Gupta AK, Ellis CN, Cooper KD, Nickoloff BJ, Ho VC, Chan LS, et al. Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. J Am Acad Dermatol. 1990;22(2 Pt 1):242–50.
60. Shapiro J. Current treatment of alopecia areata. J Investig Dermatol Symp Proc Soc Investig Dermatol Inc Eur Soc Dermatol Res. 2013;16(1):S42–4.
61. Brzezińska-Wcisło L, Bergler-Czop B, Wcisło-Dziadecka D, Lis-Święty A. New aspects of the treatment of alopecia areata. Postȩpy Dermatol Alergol. 2014;31(4):262–5.
62. Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013;169(5):992–9.
63. Navarro R, Daudén E, Gallo E, Santiago Sánchez-Mateos D, García-Diez A. Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. Skin Pharmacol Physiol. 2012;25(2):107–10.
64. Gorcey L, Spratt EAG, Leger MC. Alopecia universalis successfully treated with adalimumab. JAMA Dermatol. 2014;150(12):1341–4.
65. Ghoreishi M, Martinka M, Dutz JP. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol. 2010;163(1):57–62.
66. Kooloos WM, de Jong DJ, Huizinga TWJ, Guchelaar H-J. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today. 2007;12(3–4):125–31.
67. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.
68. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–43.
69. Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol Baltim Md 1950. 2000;164(4):1643–7.
70. Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.
71. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(4):1149–52.
72. Gupta A, Carviel J, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373–8.
73. Mackay-Wiggan J. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe alopecia areata, totalis and universalis [online]. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT02299290.
74. Mackay-Wiggan J. An open-label pilot study to evaluate the efficacy of ruxolitinib in moderate to severe alopecia areata. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01950780.
75. Ortiz-Ibáñez K, Alsina MM, Muñoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermo-Sifiliogr. 2013;104(4):304–10.
76. No authors listed. Tofacitinib. Drugs R D. 2010;10(4):271–84 (Erratum appears in Drugs R D. 2012;12(1):41–3).
77. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–91.
78. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–17.
79. Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014;15(1):103–13.
80. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994;370(6485):153–7.
81. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513–26.
82. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
83. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 2011;32(1):25–34.
84. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385–95.
85. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225–8.
86. Watt-Smith S. Dental and craniofacial applications of platelet-rich plasma. Br Dent J. 2005;199(12):799.
87. Lin SS, Montemurro NJ, Krell ES. Orthobiologics in foot and ankle surgery. J Am Acad Orthop Surg. 2016;24(2):113–22.
88. Bhanot S, Alex JC. Current applications of platelet gels in facial plastic surgery. Facial Plast Surg FPS. 2002;18(1):27–33.
89. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2004;62(4):489–96.
90. Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006;43(2):105–15.
91. Takakura N, Yoshida H, Kunisada T, Nishikawa S, Nishikawa SI. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol. 1996;107(5):770–7.
92. Li ZJ, Choi H-I, Choi D-K, Sohn K-C, Im M, Seo Y-J, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2012;38(7 Pt 1):1040–6.
93. Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690–4.
94. Sohn K-C, Shi G, Jang S, Choi D-K, Lee Y, Yoon T-J, et al. Pitx2, a beta-catenin-regulated transcription factor, regulates the differentiation of outer root sheath cells cultured in vitro. J Dermatol Sci. 2009;54(1):6–11.
95. El-Sharkawy H, Kantarci A, Deady J, Hasturk H, Liu H, Alshahat M, et al. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol. 2007;78(4):661–9.
96. Amable PR, Carias RBV, Teixeira MVT, da Cruz Pacheco I, Corrêa do Amaral RJF, Granjeiro JM, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67.
97. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem (Tokyo). 2010;147(6):781–92.
98. Ovidio R d’. Limited effectiveness of platelet-rich-plasma treatment on chronic severe alopecia areata. Hair Ther Transplant [online]. 2014 [cited 2016 Feb 18];04(01). Available from: http://www.omicsgroup.org/journals/limited-effectiveness-of-plateletrichplasma-treatment-on-chronic-severe-alopecia-areata-2167-0951.1000116.php?aid=24661.
99. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010;62(2):191–202 (quiz 203–4).
100. Singh S. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. Indian J Plast Surg Off Publ Assoc Plast Surg India. 2015;48(1):57–9.
101. Gkini M-A, Kouskoukis A-E, Rigopoulos D, Kouskoukis K. Platelet-rich plasma as a potential treatment for noncicatricial alopecias. Int J Trichol. 2015;7(2):54–63.
102. Mackay-Wiggan J. An open-label single-arm clinical trial to evaluate the efficacy of abatacept in moderate to severe patch type alopecia areata [online]. 2013 [cited 2016 Feb 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02018042?term=NCT02018042&rank=1.
103. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5(3):185–6.
104. Novák Z, Bónis B, Baltás E, Ocsovszki I, Ignácz F, Dobozy A, et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B. 2002;67(1):32–8.
105. McMichael AJ. Excimer laser: a module of the alopecia areata common protocol. J Investig Dermatol Symp Proc. 2013;16(1):S77–9.
106. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol. 2009;26(5):547–50.
107. Byun JW, Moon JH, Bang CY, Shin J, Choi GS. Effectiveness of 308-nm excimer laser therapy in treating alopecia areata, determined by examining the treated sides of selected alopecic patches. Dermatol Basel Switz. 2015;231(1):70–6.
108. Shin BS, Furuhashi T, Nakamura M, Torii K, Morita A. Impaired inhibitory function of circulating CD4+CD25+ regulatory T cells in alopecia areata. J Dermatol Sci. 2013;70(2):141–3.
109. Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748–51.
110. Ali A, Martin JM. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol. 2010;9(1):62–4.
111. Robins DN. Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol. 2007;6(9):946–7.
112. Lattouf C, Jimenez JJ, Tosti A, Miteva M, Wikramanayake TC, Kittles C, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol. 2015;72(2):359–61.
113. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol. 2004;13(6):337–9.
114. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med. 2012;271(1):32–42.
115. Schafer PH, Day RM. Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol. 2013;68(6):1041–2.
116. Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. 2015;77(1):74–6.
117. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201–10.